EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis

Wenxi Wang, Hua Yang, Tenzin Passang, Yiwen Li, Hanwen Zhang, Shayna E Jankowski, Fanyuan Zeng, Shuhua Wang, Po-Chih Hsu, Jian-Ming Li, Zihan Chen, Gregory B Lesinski und 5 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Wenxi Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; Department of Oncology, Xiangya Hospital…. Hauptthemen laut MEDLINE: Liver Neoplasms, Melanoma, Vasoactive Intestinal Peptide, Receptors, Vasoactive Intestinal Peptide, Type II. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Abraham J & Phyllis Katz Foundation, National Cancer Institute, Emory University Winship Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveal melanoma (UVM) is resistant to immune checkpoint therapy and chemotherapy, resulting in high mortality rates, primarily due to liver metastases. While vasoactive intestinal peptide (VIP) signaling has been identified as an immune checkpoint and therapeutic target in pancreatic cancer, its role in melanoma remains unexplored. This study investigated the impact of a novel VIP receptor antagonist, ANT308, on melanoma cell behavior and tumor growth. Using both murine and human UVM/cutaneous melanoma cell lines, we examined the inhibition of VIP receptor signaling and its effects on cell migration and proliferation in vitro. Mechanistically, ANT308 downregulated melanoma cell adhesion molecule (MCAM) and N-cadherin expression at both the RNA and protein levels, as demonstrated by RNA sequencing and Western blot analyses. Knockdown of the VIP receptor VPAC2 in mouse and human melanoma cells produced similar effects on cell migration, proliferation, and MCAM protein expression, further implicating VIP-VPAC2 signaling in tumor progression. In vivo studies revealed that ANT308 treatment decreased MCAM expression in intraocular primary tumors, reduced the number and size of liver metastases following intraocular or subcutaneous melanoma injection, and showed a trend toward reduced tumor volume at the primary tumor site. In conclusion, our findings indicate that VIP receptor signaling promotes liver metastasis in melanoma, and targeting this pathway with VIP receptor antagonists may represent a novel therapeutic strategy for treating metastatic UVM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsMelanomaVasoactive Intestinal PeptideReceptors, Vasoactive Intestinal Peptide, Type IIUveal NeoplasmsAnimalsHumansMiceCell ProliferationCell Line, TumorSignal TransductionCell MovementUveal MelanomaXenograft Model Antitumor AssaysGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Liver metastasisMelanomaUveal melanomaVIP receptorVasoactive intestinal peptide

Substanzen

Vasoactive Intestinal PeptideReceptors, Vasoactive Intestinal Peptide, Type II

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; Department of Oncology, Xiangya Hospital, Central South University (CSU), Changsha, China; Department of Radia…
  • Department of Ophthalmology, Emory University, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; Department of Oncology, Xiangya Hospital, Central South University (CSU), Changsha, China.
  • Department of Pathology, Wellstar Health System, China.
  • Department of Ophthalmology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Förderung

  • The Abraham J & Phyllis Katz Foundation
  • National Cancer Institute
  • Emory University Winship Cancer Institute
  • National Institutes of Health
  • Integrated Cellular Imaging Core, Emory University

Zitieren

APA

Wang, W., Yang, H., Passang, T., Li, Y., Zhang, H., Jankowski, S. E., Zeng, F., Wang, S., Hsu, P. C., Li, J. M., Chen, Z., Lesinski, G. B., Mendoza, P. R., Li, Y., Giver, C. R., Grossniklaus, H. E., & Waller, E. K. (2025). Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217855

Vancouver

Wang W, Yang H, Passang T, Li Y, Zhang H, Jankowski SE, et al. Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217855

BibTeX
@article{Wang2025,
  author = {Wang, Wenxi and Yang, Hua and Passang, Tenzin and Li, Yiwen and Zhang, Hanwen and Jankowski, Shayna E and Zeng, Fanyuan and Wang, Shuhua and Hsu, Po-Chih and Li, Jian-Ming and Chen, Zihan and Lesinski, Gregory B and Mendoza, Pia R and Li, Ying and Giver, Cynthia R and Grossniklaus, Hans E and Waller, Edmund K},
  title = {Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217855}
}
Kostenlos starten →